Could urinary ACE2 protein level help identify individuals susceptible to SARS-CoV-2 infection and complication?

Ni, Xiaohua; Sun, Changqing; Tian, Yaping; Huang, Yanjie; Gong, Tongqing; Song, Lei; Yang, Xing; Li, Kai; Zheng, Nairen; Wang, Jianping; Wu, Hao; Zhang, Ruoxian; Wang, Yi; Wang, Guangshun; Qin, Jun

doi:10.1007/s11427-020-1759-4

Cited by 3 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18,40 It has been reported that U-ACE2 is positively associated with systolic blood pressure, parameters of glucose metabolism, and U-ACR. 14,21,51 We confirmed independent and positive associations of U-ACE2 with systolic blood pressure, HbA1c, and U-ACR in the present study.…”

Section: Discussionsupporting

confidence: 88%

Distinct Regulation of U-ACE2 and P-ACE2 (Urinary and Plasma Angiotensin-Converting Enzyme 2) in a Japanese General Population

et al. 2021

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 in coronavirus disease 2019 invades the host through ACE (angiotensin-converting enzyme) 2 as the host cellular receptor for a viral spike protein. ACE2 converts angiotensin II to angiotensin-(1–7) and cleaved ACE2 is detectable in urine and plasma. However, regulation of U-ACE2 (urinary ACE2) and P-ACE2 (plasma ACE2) and their alterations by renin-angiotensin-aldosterone system inhibitors remain unclear. We simultaneously investigated U-ACE2 and P-ACE2 in 605 Japanese participants (male/female: 280/325, mean age: 65±15 years) in the Tanno-Sobetsu cohort study in 2017. Males had significantly lower U-ACE2 and higher P-ACE2 than did females. There was no significant correlation between U-ACE2 and P-ACE2. P-ACE2 was significantly lower in subjects treated with renin-angiotensin-aldosterone system inhibitors than in those not treated with renin-angiotensin-aldosterone system inhibitors, but there was no significant difference in U-ACE2 between the groups. Multivariable regression analyses showed that female sex, high levels of systolic blood pressure, hemoglobin A1c, and urinary albumin-to-creatinine ratio, and low uric acid level were independent predictors of high U-ACE2 level and that high levels of γ-glutamyl transpeptidase, estimated glomerular filtration rate, and uric acid were independent predictors of high P-ACE2 level. In conclusion, U-ACE2 and P-ACE2 are distinctly regulated and the use of renin-angiotensin-aldosterone system inhibitors is not an independent predictor of their levels in a Japanese general population. U-ACE2 is associated with high blood pressure, high glucose level, and microalbuminuria, and low urate level, whereas P-ACE2 is associated with liver dysfunction, high glomerular filtration rate, and high urate level.

show abstract

Section: Discussionsupporting

confidence: 88%

Distinct Regulation of U-ACE2 and P-ACE2 (Urinary and Plasma Angiotensin-Converting Enzyme 2) in a Japanese General Population

et al. 2021

View full text Add to dashboard Cite

show abstract

“…found urinary peptides significantly associated with SARS‐CoV‐2 infection and may be a valuable biomarker to assess and predict the severity of COVID‐19 disease course. Also, Ni et al 202 . revealed that ACE2 is detectable by MS‐based proteomic approaches in urinary samples, and further verified the feasibility of urinary samples to predict disease severity.…”

Section: Application Of Proteomics In the Emerging Pandemicmentioning

confidence: 82%

“…Also, Ni et al. 202 revealed that ACE2 is detectable by MS‐based proteomic approaches in urinary samples, and further verified the feasibility of urinary samples to predict disease severity.…”

Section: Application Of Proteomics In the Emerging Pandemicmentioning

confidence: 84%

Application of omics technology to combat the COVID‐19 pandemic

Yang

Yan²,

Zhong³

2021

MedComm

View full text Add to dashboard Cite

As of August 27, 2021, the ongoing pandemic of coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has spread to over 220 countries, areas, and territories. Thus far, 214,468,601 confirmed cases, including 4,470,969 deaths, have been reported to the World Health Organization. To combat the COVID‐19 pandemic, multiomics‐based strategies, including genomics, transcriptomics, proteomics, and metabolomics, have been used to study the diagnosis methods, pathogenesis, prognosis, and potential drug targets of COVID‐19. In order to help researchers and clinicians to keep up with the knowledge of COVID‐19, we summarized the most recent progresses reported in omics‐based research papers. This review discusses omics‐based approaches for studying COVID‐19, summarizing newly emerged SARS‐CoV‐2 variants as well as potential diagnostic methods, risk factors, and pathological features of COVID‐19. This review can help researchers and clinicians gain insight into COVID‐19 features, providing direction for future drug development and guidance for clinical treatment, so that patients can receive appropriate treatment as soon as possible to reduce the risk of disease progression.

show abstract

A urinary proteomic landscape of COVID-19 progression identifies signaling pathways and therapeutic options

Liu

Song

Zheng

et al. 2022

Sci. China Life Sci.

View full text Add to dashboard Cite

Signaling pathway alterations in COVID-19 of living humans as well as therapeutic targets of the host proteins are not clear. We analyzed 317 urine proteomes, including 86 COVID-19, 55 pneumonia and 176 healthy controls, and identified specific RNA virus detector protein DDX58/RIG-I only in COVID-19 samples. Comparison of the COVID-19 urinary proteomes with controls revealed major pathway alterations in immunity, metabolism and protein localization. Biomarkers that may stratify severe symptoms from moderate ones suggested that macrophage induced inflammation and thrombolysis may play a critical role in worsening the disease. Hyper activation of the TCA cycle is evident and a macrophage enriched enzyme CLYBL is up regulated in COVID-19 patients. As CLYBL converts the immune modulatory TCA cycle metabolite itaconate through the citramalyl-CoA intermediate to acetyl-CoA, an increase in CLYBL may lead to the depletion of itaconate, limiting its anti-inflammatory function. These observations suggest that supplementation of itaconate and inhibition of CLYBL are possible therapeutic options for treating COVID-19, opening an avenue of modulating host defense as a means of combating SARS-CoV-2 viruses. Supporting Information The supporting information is available online at 10.1007/s11427-021-2070-y. The supporting materials are published as submitted, without typesetting or editing. The responsibility for scientific accuracy and content remains entirely with the authors.

show abstract

Could urinary ACE2 protein level help identify individuals susceptible to SARS-CoV-2 infection and complication?

Cited by 3 publications

References 4 publications

Distinct Regulation of U-ACE2 and P-ACE2 (Urinary and Plasma Angiotensin-Converting Enzyme 2) in a Japanese General Population

Distinct Regulation of U-ACE2 and P-ACE2 (Urinary and Plasma Angiotensin-Converting Enzyme 2) in a Japanese General Population

Application of omics technology to combat the COVID‐19 pandemic

A urinary proteomic landscape of COVID-19 progression identifies signaling pathways and therapeutic options

Contact Info

Product

Resources

About